SVB Leerink and Oncology

Selected healthcare news for the capital firm - SVB Leerink, and the healthcare topic - Oncology. We have 328 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/12/2022 Bolt Biotherapeutics (NASDAQ:BOLT) Upgraded by Zacks Investment Research to ‚ÄúBuy‚Äù ... oncology company. It engages in the discovery, development, and commercialization of pharmaceutical products. The company‚Aos principal product includes BDC-1001. Bolt Biotherapeutics Inc. is based in Redwood city, California. ‚AuA number of other research analysts also recently commented on the company. SVB Leerink reaffirmed a buy rating on shares of Bolt Biotherapeutics in a report on Thursday, December 9th. Morgan Stanley downgraded Bolt Biotherapeutics from an overweight rating ...
12/29/2021 Aura Biosciences (NASDAQ:AURA) Stock Price Up 7.7% - Ticker Report Ticker Report ... 168,192 shares. The stock had previously closed at $16.04.Several equities research analysts have recently weighed in on AURA shares. SVB Leerink started coverage on Aura Biosciences in a research report on Tuesday, November 23rd ... Profile ( NASDAQ:AURA )Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system ...
12/29/2021 Aura Biosciences (NASDAQ:AURA) Stock Price Up 7.7% - Watch List News ... of 168,192 shares. The stock had previously closed at $16.04.AURA has been the subject of several recent analyst reports. SVB Leerink initiated coverage on shares of Aura Biosciences in a research note on Tuesday ... Profile ( NASDAQ:AURA )Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system ...
12/13/2021 Cullinan Oncology (NASDAQ:CGEM) Sets New 52-Week Low at $15.81 Cullinan Oncology, Inc. (NASDAQ:CGEM)‚Aos share price reached a new 52-week low during trading on Monday . The company traded as low as $15.81 and last traded at $16.07, with a volume of 7194 shares. The stock had previously closed at $16.82.Separately, SVB Leerink reissued a ‚Aubuy‚Au rating and issued a $54.00 price objective on shares of Cullinan Oncology in a research note on Monday, November 15th ...
12/8/2021 Cullinan Oncology (NASDAQ:CGEM) Hits New 52-Week Low at $15.92 Dakota Financial News Cullinan Oncology, Inc. (NASDAQ:CGEM)‚Aos stock price reached a new 52-week low on Monday . The stock traded as low as $15.92 and last traded at $15.92, with a volume of 240 shares changing hands. The stock had previously closed at $16.21.Separately, SVB Leerink reissued a ‚Aubuy‚Au rating and issued a $54.00 target price on shares of Cullinan Oncology in a research note on Monday, November 15th ...
12/3/2021 Celyad Oncology Shares Gain After Fortress Injects $32M Via Equity Benzinga Celyad Oncology SA (NASDAQ: CYAD ) has announced a private placement worth $32.5 million (about ‚C¨28.7 million) with Fortress Investment Group. The offering includes the private placement of 6.5 million shares and will close by ... the transaction, Fortress will hold 28.8% of the Company's shares.- SVB Leerink acted as the exclusive placement agent for the private placement.- The Company believes that private placement proceeds, [cash and cash equivalents of ‚C ...
10/19/2021 Elevation Oncology (NASDAQ:ELEV) Stock Rating Lowered by Zacks Investment Research - The Cerbat Gem ... Oncology (NASDAQ:ELEV) from a buy rating to a hold rating in a research report sent to investors on Friday morning, Zacks.com reports.According to Zacks, ‚AuElevation Oncology Inc. is a clinical stage biopharmaceutical company. It focused on the development of precision medicines for patients with genomically defined cancers. Elevation Oncology Inc. is based in NEW YORK. ‚AuSeveral other research analysts also recently weighed in on ELEV. SVB Leerink ...
10/18/2021 Bolt Biotherapeutics (NASDAQ:BOLT) Rating Increased to Hold at Zacks Investment Research - The Cerbat Gem ... oncology company. It engages in the discovery, development, and commercialization of pharmaceutical products. The company‚Aos principal product includes BDC-1001. Bolt Biotherapeutics Inc. is based in Redwood city, California. ‚AuA number of other analysts have also recently commented on BOLT. SVB Leerink upped their price target on Bolt Biotherapeutics from $34.00 to $35.00 and gave the company an ‚Auoutperform‚Au rating in a research note on Monday, August ...
10/10/2021 Kura Oncology (NASDAQ:KURA) Cut to ‚ÄúSell‚Äù at Zacks Investment Research Zacks Investment Research lowered shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a sell rating in a report released on Wednesday morning, Zacks.com reports.According to Zacks, ‚AuKura Oncology, Inc. is a ... AuSeveral other brokerages have also issued reports on KURA. SVB Leerink boosted their price objective on shares of Kura Oncology from $40.00 to $41.00 and gave the company an outperform rating in a report ...
10/9/2021 Kura Oncology (NASDAQ:KURA) Downgraded by Zacks Investment Research to ‚ÄúSell‚Äù Zacks Investment Research cut shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a sell rating in a research note released on Wednesday morning, Zacks.com reports. According to Zacks, ‚AuKura Oncology, Inc. is ... research analysts have also issued research reports about the company. SVB Leerink upped their price objective on Kura Oncology from $40.00 to $41.00 and gave the stock an outperform rating in a report on Friday ...
10/7/2021 BridgeBio Pharma (NASDAQ:BBIO) Raised to ‚ÄúBuy‚Äù at Zacks Investment Research - The Cerbat Gem ... Zacks, ‚AuBridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company‚Aos product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and ... the stock in a research report on Friday, September 10th. SVB Leerink increased their target price on shares of BridgeBio Pharma from $66.00 to $68.00 and gave the stock an ‚Auoutperform‚Au rating in a ...
9/25/2021 Innate Pharma (NASDAQ:IPHA) Raised to ‚ÄúHold‚Äù at Zacks Investment Research - Slater Sentinel ... a research note issued to investors on Tuesday, Zacks.com reports.According to Zacks, ‚AuInnate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer ... Pharma in a research report on Thursday, September 16th. Finally, SVB Leerink boosted their target price on shares of Innate Pharma from $7.00 to $9.00 and gave the stock an outperform rating in a research ...
9/20/2021 Why AstraZeneca Shares Are Trading Higher Today Benzinga ... is trading higher Monday after the company announced its Enhertu data that was presented at the European Society for Medical Oncology showed reduced risk of disease progression by 72% in patients with HER2-Positive metastatic ... therapeutic classes including gastrointestinal, diabetes, cardiovascular, respiratory, cancer and immunology. SVB Leerink analyst Andrew Berens maintained AstraZeneca with an Outperform rating and raised the price target from $69 to $71. AZN Price Action: AstraZeneca has ...
9/20/2021 48 Biggest Movers From Friday Benzinga ... Oncology (ESMO21) Congress 2021. SVB Leerink maintained Innate Pharma with an Outperform and raised the price target from $7 to $9. - ForgeRock, Inc. (NYSE: [FORG] ) jumped 29.2% to close at $47.15. The company recently priced its IPO at $25 per share. - X Financial (NYSE: [XYF] ) surged 21.5% to settle at $4.80. - Spire Global, Inc. (NYSE: [SPIR] ) rose 202.% to close at $13.71. Spire Global recently announced plans to acquire exactEarth ...
9/18/2021 Century Therapeutics (NASDAQ:IPSC) Cut to ‚ÄúSell‚Äù at Zacks Investment Research - Stock Observer ... Therapeutics Inc. is a cell therapy company. It involved in developing induced pluripotent stem cell -derived cell therapies in immuno-oncology. Century Therapeutics Inc. is based in PHILADELPHIA. ‚AuGet Century Therapeutics alerts: Other equities ... overweight rating and a $38.00 target price on the stock. SVB Leerink reissued a buy rating on shares of Century Therapeutics in a research report on Sunday, August 15th. Finally, Bank of America initiated coverage ...
9/18/2021 Anheuser-Busch InBev SA/NV (EBR:ABI) Given a ‚Ǩ60.00 Price Target at Deutsche Bank Aktiengesellschaft | Daily Political Daily Political ... Therapeutics Inc. is a cell therapy company. It involved in developing induced pluripotent stem cell -derived cell therapies in immuno-oncology. Century Therapeutics Inc. is based in PHILADELPHIA. ‚AuA number of other equities analysts have ... overweight rating and a $40.00 target price for the company. SVB Leerink reaffirmed a buy rating on shares of Century Therapeutics in a research report on Sunday, August 15th. Finally, Piper Sandler began coverage on ...
9/17/2021 Century Therapeutics (NASDAQ:IPSC) Downgraded by Zacks Investment Research ... Therapeutics Inc. is a cell therapy company. It involved in developing induced pluripotent stem cell -derived cell therapies in immuno-oncology. Century Therapeutics Inc. is based in PHILADELPHIA. ‚Au IPSC has been the topic of ... overweight rating and a $38.00 price objective on the stock. SVB Leerink reissued a buy rating on shares of Century Therapeutics in a report on Sunday, August 15th. Finally, JPMorgan Chase & Co. started coverage on ...
9/16/2021 Crescendo to Participate in Upcoming Investor Conferences Yahoo News ... oncology company developing novel, targeted T cell enhancing therapeutics, today announces that senior members of the executive team will be participating at the following events. They also look forward to meeting investors to discuss the Company‚Aos business strategy, technology, discovery platform and development programmes.Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, 23 September 2021Presentation at 9:05 am EDT, 2:05 pm BSTSVB Leerink Biopharma Private Company Connect ...
9/16/2021 Crescendo to Participate in Upcoming Investor Conferences Business Wire ... oncology company developing novel, targeted T cell enhancing therapeutics, today announces that senior members of the executive team will be participating at the following events. They also look forward to meeting investors to discuss the Company‚Aos business strategy, technology, discovery platform and development programmes. - Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, 23 September 2021 Presentation at 9:05 am EDT, 2:05 pm BST - SVB Leerink Biopharma Private Company Connect ...
9/16/2021 Crescendo to Participate in Upcoming Investor Conferences | Business Wire Business Wire ... oncology company developing novel, targeted T cell enhancing therapeutics, today announces that senior members of the executive team will be participating at the following events. They also look forward to meeting investors to discuss the Company‚Aos business strategy, technology, discovery platform and development programmes.Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, 23 September 2021Presentation at 9:05 am EDT, 2:05 pm BST SVB Leerink Biopharma Private Company Connect ...
9/16/2021 Century Therapeutics (NASDAQ:IPSC) Downgraded by Zacks Investment Research ... oncology. Century Therapeutics Inc. is based in PHILADELPHIA. ‚Au A number of other brokerages have also recently issued reports on IPSC. SVB Leerink reissued a ‚Aubuy‚Au rating on shares of Century Therapeutics in a research report on Sunday, August 15th. JPMorgan Chase & Co. initiated coverage on shares of Century Therapeutics in a research report on Tuesday, July 13th. They set an ‚Auoverweight‚Au rating and a $40.00 price target ...
9/15/2021 Century Therapeutics (NASDAQ:IPSC) Downgraded to Sell at Zacks Investment Research ... oncology. Century Therapeutics Inc. is based in PHILADELPHIA. ‚Au A number of other brokerages have also recently weighed in on IPSC. JPMorgan Chase & Co. began coverage on Century Therapeutics in a research note on Tuesday, July 13th. They set an overweight rating and a $40.00 price objective for the company. SVB Leerink restated a buy rating on shares of Century Therapeutics in a research note on Sunday, August 15th. Piper ...
9/12/2021 Innate Pharma (NASDAQ:IPHA) Downgraded by Zacks Investment Research to ‚ÄúSell‚Äù ... oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company‚Aos commercial-stage product includes Lumoxiti. Innate Pharma S.A. is based in Marseille, France. ‚AuSeparately, SVB Leerink upgraded Innate Pharma from a market perform rating to an outperform rating and set a $7.00 price objective on the stock in a report on Thursday, September 2nd.[IPHA] opened at $6.02 on Thursday. The ...
9/12/2021 Innate Pharma (NASDAQ:IPHA) Cut to ‚ÄúSell‚Äù at Zacks Investment Research - The Cerbat Gem ... oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company‚Aos commercial-stage product includes Lumoxiti. Innate Pharma S.A. is based in Marseille, France. ‚AuSeparately, SVB Leerink raised shares of Innate Pharma from a market perform rating to an outperform rating and set a $7.00 target price on the stock in a research report on Thursday, September 2nd.NASDAQ IPHA opened at ...
9/5/2021 Innate Pharma (NASDAQ:IPHA) Sets New 52-Week High at $6.94 ... last traded at $6.94, with a volume of 189582 shares trading hands. The stock had previously closed at $4.18.Separately, SVB Leerink raised shares of Innate Pharma from a ‚Aumarket perform‚Au rating to an ... discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the ...